European Commission Approves Merck’s Keytruda-Padcev Combo for First-Line Urothelial Carcinoma Treatment
Merck & Co., Inc. (NYSE: MRK), a global healthcare leader based in the United States,...
Merck
Henlius Biotech’s HLX17 Biosimilar to MSD’s Keytruda Wins NMPA Clinical Trial Approval
SHANGHAI—Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clinical trial approval...
Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results
US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...
MSD to Acquire Curon Biopharmaceutical’s CD3 x CD19 Bispecific Antibody CN201 in USD 1.3 Billion Deal
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic acquisition agreement with Shanghai-based...
Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance
Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...
CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology
CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...
Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079
Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...
Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...
I-Mab Shakes Up Leadership with New Chairman and Interim CEO Appointments
I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company, has announced significant changes to its leadership structure....
Merck KGaA Launches First GMP Cell Culture Medium Production Line in China
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of...
Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted
Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...
Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter
Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...
Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial
Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...
MSD’s Capvaxive Vaccine Targets 21 Serotypes of Streptococcus Pneumoniae
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced...
MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...
Merck Boosts Global Distribution Capabilities with €180 Million Expansion of German Center
Merck KGaA (ETR: MRK), the German life science and technology company, announced last week a...
MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...
MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...